NCT06305832View on ClinicalTrials.gov

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

September 7, 2023

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Prostate CancerBiochemical Recurrence
Interventions
DRUG

Rezvilutamide

Specifications of 80 mg; orally, once a day

DRUG

Androgen deprivation therapy (ADT)

Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator,and the dose and frequency of administration will be consistent with the prescription information

RADIATION

SRT

SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)

Trial Locations (2)

210000

RECRUITING

Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing

RECRUITING

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER